Adriamycin in the treatment of cancer.
Adriamycin in the treatment of cancer.
复制标题
阿霉素治疗癌症。
DOI：
--
复制
发表时间：
1976
期刊：
影响因子：
--
通讯作者：
Geoffrey Falkson
中科院分区：
文献类型：
--
作者：
van Dyk Jj;van der Merwe Am;Falkson Hc;Geoffrey Falkson
阿霉素是一种新型抗癌抗生素，对实体瘤具有广泛的活性谱。本文报道了159例经组织学证实为晚期转移性恶性肿瘤患者使用该药物的结果。在骨和软组织肉瘤患者中取得了令人鼓舞的结果（12/22）。在间皮瘤（3/9）和肺癌（5/15）中也观察到了疗效。还治疗了多种其他肿瘤，并报道了在神经母细胞瘤、睾丸肿瘤、胃癌、乳腺癌和肾母细胞瘤中取得的结果。结合缓解率和毒性对治疗进行了讨论。介绍了72例晚期乳腺癌患者接受阿霉素联合其他化疗药物治疗的结果。17例原发性肝癌患者也接受了阿霉素治疗。到目前为止，它似乎是唯一一种能显著提高这种难治性癌症患者生存时间的化疗药物。还讨论了阿霉素对骨肉瘤的预防性使用。
Adriamycin is a new anticancer antibiotic with a wide spectrum of activity against solid tumours. The results obtained with this agent in 159 patients with histologically confirmed advanced metastastic malignancies are reported. Encouraging results were obtained in patients with sarcomas of bone and soft tissue (12/22). Response was also seen in mesothelioma (3/9) and lung cancer (5/15). A variety of other neoplasms was also treated and results obtained in neuroblastoma, testicular tumours, stomach carcinoma, breast cancer and nephroblastoma are reported. Treatment is discussed, with reference to response rates and toxicity. Results in 72 patients with advanced breast cancer, who received adriamycin in combination with other chemotherapeutic agents, are presented. Seventeen patients with primary liver cancer were also treated with adriamycin. To date, this is the only chemotherapeutic agent that appears to significantly improve survival times in patients with this resistant form of cancer. The prophylactic use of adriamycin against osteogenic sarcoma is also discussed.